KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Accumulated Expenses (2019 - 2026)

GoodRx Holdings' Accumulated Expenses history spans 7 years, with the latest figure at $86.7 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 4.05% to $86.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $86.7 million, a 4.05% increase, with the full-year FY2025 number at $86.7 million, up 4.05% from a year prior.
  • Accumulated Expenses hit $86.7 million in Q4 2025 for GoodRx Holdings, down from $143.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for GDRX hit a ceiling of $143.4 million in Q3 2025 and a floor of $9.6 million in Q1 2021.
  • Historically, Accumulated Expenses has averaged $63.8 million across 5 years, with a median of $68.4 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: soared 273.26% in 2021 and later grew 4.05% in 2025.
  • Tracing GDRX's Accumulated Expenses over 5 years: stood at $15.5 million in 2021, then soared by 206.74% to $47.5 million in 2022, then soared by 50.09% to $71.3 million in 2023, then grew by 16.83% to $83.3 million in 2024, then rose by 4.05% to $86.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for GDRX at $86.7 million in Q4 2025, $143.4 million in Q3 2025, and $95.7 million in Q2 2025.